Le site français est toujours en construction. Rendez-vous en janvier ! Pour nous contacter, cliquer ici.
Pour accéder à la plateforme Pharmaciens, cliquer ici.


 Inodiab study: improvement of type 2 diabetes patients’ adherence

Inodiab is the first French randomized study on the effects of a personalized SMS patient engagement program piloted by pharmacists.

It demonstrates a positive and significant impact on the adherence of type 2 diabetic patients (T2D) as well as on their Body Mass Index (BMI).


The infographic:

bandeau ino en


Get the key findings and share with others

Presentation of the results: 

An increase in the MMAS-8 score (indicator of adherence) of patients in the SMS group was observed between the time intervals 0 and 1 month and 0 and 3 months and was significantly higher than in the control group. 

Among the biological data measured, body mass index decreased significantly in the group of patients receiving the messages compared to the control group between 0 and 3 months. This benefit was not observed between 0 and 6 months. HDL cholesterol, glycated hemoglobin, and physical activity (measured by the International Physical Activity Questionnaire IPAQ-SF) did not show significant differences between the two study groups.

The personalization of this SMS support service, made possible by a detailed analysis of individual behavioral levers, coupled with the intervention of pharmacistsled to a significant improvement in patients' medical adherence and physical condition (BMI). 


Access the scientific publication



See also

Scientific communications

SPUR™ Phase 2 US study: publication’s results


(R)evolution in healthtech: pharma companies must take the reins


Already 10 Years Spent Together

Accès plateformes